Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study

To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study.

[1]  K. Iwasaki,et al.  Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database , 2020, Clinical epidemiology.

[2]  Kamlesh Khunti,et al.  Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[3]  M. Kulldorff,et al.  The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care , 2019, Endocrinology, diabetes & metabolism.

[4]  S. Schneeweiss,et al.  P5003Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study , 2019, European Heart Journal.

[5]  G. Lip,et al.  Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. , 2019, Chest.

[6]  Akshay S. Desai,et al.  Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. , 2019, Circulation.

[7]  M. Kulldorff,et al.  249-OR: Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study , 2019, Diabetes.

[8]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[9]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[10]  C. Wanner,et al.  Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial , 2019, Journal of diabetes investigation.

[11]  M. Kulldorff,et al.  Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. , 2018, Circulation.

[12]  Moon-Kyu Lee,et al.  Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials , 2018, Journal of diabetes investigation.

[13]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[14]  M. Schuemie,et al.  Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D) , 2018, Diabetes, obesity & metabolism.

[15]  J. Shaw,et al.  Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. , 2018, Journal of the American College of Cardiology.

[16]  S. Suissa.  Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias. , 2018, Circulation.

[17]  S. Schneeweiss,et al.  Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records , 2018, Diabetes, obesity & metabolism.

[18]  J. Park,et al.  Trends in the prevalence of metabolic syndrome and its components in South Korea: Findings from the Korean National Health Insurance Service Database (2009–2013) , 2018, PloS one.

[19]  J. Shaw,et al.  Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study , 2018 .

[20]  S. Schneeweiss,et al.  Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study , 2018, British Medical Journal.

[21]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[22]  S. Suissa.  Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? , 2017, Diabetes Care.

[23]  K. Khunti,et al.  Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs , 2017, Circulation.

[24]  H. Woerle,et al.  Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　- Results From EMPA-REG OUTCOME®. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[25]  R. Nishimura,et al.  Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials , 2016, Diabetes, obesity & metabolism.

[26]  T. Yanase,et al.  Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database , 2016, Journal of diabetes investigation.

[27]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[28]  Merlin C. Thomas,et al.  Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease , 2016, Nature Reviews Nephrology.

[29]  Ki-Up Lee,et al.  Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service , 2016, Diabetes & metabolism journal.

[30]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[31]  H. Shimokawa,et al.  Heart failure as a general pandemic in Asia , 2015, European journal of heart failure.

[32]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[33]  J. Chan,et al.  Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States , 2013, Annals of the New York Academy of Sciences.

[34]  R. Grempler,et al.  Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors , 2012, Diabetes, obesity & metabolism.

[35]  J. Salomon,et al.  Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis , 2010, PLoS medicine.

[36]  P. Austin,et al.  Assessing balance in measured baseline covariates when using many‐to‐one matching on the propensity‐score , 2008, Pharmacoepidemiology and drug safety.

[37]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[38]  Jennifer Y. Liu,et al.  Ethnic disparities in diabetic complications in an insured population. , 2002, JAMA.

[39]  Chih-Cheng Hsu,et al.  Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban , 2018, Thrombosis and Haemostasis.

[40]  Tim Nolan,et al.  International Diabetes Federation. , 2013, Diabetes research and clinical practice.